Ki-wook Oh

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Functional impact of the ATP1A3-p.A813V variant: insights into a calcium-driven hyperexcitability cascade in rapid-onset dystonia-Parkinsonism.

Functional impact of the ATP1A3-p.A813V variant: insights into a calcium-driven hyperexcitability cascade in rapid-onset dystonia-Parkinsonism.

Journal: Journal of translational medicine
Published: January 21, 2026

Monoclonal Gammopathy in Amyotrophic Lateral Sclerosis: No Impact on Clinical Progression and Immunotherapy Outcomes.

Monoclonal Gammopathy in Amyotrophic Lateral Sclerosis: No Impact on Clinical Progression and Immunotherapy Outcomes.

Journal: European journal of neurology
Published: May 06, 2025

Mutations in NEK1 cause ciliary dysfunction as a novel pathogenic mechanism in amyotrophic lateral sclerosis.

Mutations in NEK1 cause ciliary dysfunction as a novel pathogenic mechanism in amyotrophic lateral sclerosis.

Journal: Molecular neurodegeneration
Published: February 17, 2025

miRNA-214 to predict progression and survival in ALS.

miRNA-214 to predict progression and survival in ALS.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: October 07, 2024

Optimal Therapeutic Strategy of Bone Marrow-Originated Autologous Mesenchymal Stromal/Stem Cells for ALS.

Optimal Therapeutic Strategy of Bone Marrow-Originated Autologous Mesenchymal Stromal/Stem Cells for ALS.

Journal: Stem cells translational medicine
Published: September 30, 2023

An analysis of variants in TARDBP in the Korean population with amyotrophic lateral sclerosis: comparison with previous data.

An analysis of variants in TARDBP in the Korean population with amyotrophic lateral sclerosis: comparison with previous data.

Journal: Scientific reports
Published: July 22, 2023

Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study.

Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study.

Journal: Frontiers in aging neuroscience
Published: January 20, 2023

Role of NCKAP1 in the Defective Phagocytic Function of Microglia-Like Cells Derived from Rapidly Progressing Sporadic ALS.

Role of NCKAP1 in the Defective Phagocytic Function of Microglia-Like Cells Derived from Rapidly Progressing Sporadic ALS.

Journal: Molecular neurobiology
Published: October 21, 2022

Clinical and genetic characteristics of amyotrophic lateral sclerosis patients with ANXA11 variants.

Clinical and genetic characteristics of amyotrophic lateral sclerosis patients with ANXA11 variants.

Journal: Brain communications
Published: April 14, 2022

Gelsolin variant amyloidosis mimicking progressive bulbar palsy.

Gelsolin variant amyloidosis mimicking progressive bulbar palsy.

Journal: Muscle & nerve
Published: April 02, 2022

Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial.

Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial.

Journal: Trials
Published: November 21, 2021

De novo mutations in SOD1 are a cause of ALS.

De novo mutations in SOD1 are a cause of ALS.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: July 05, 2021
Showing 1-12 of 43

Last Updated: 09/26/2026